P-glycoprotein inhibitors and Strong 3A4 inhibitor
Not addressed in Package Insert
Avoid
Reduce dose in for those starting on the full dose of 5 mg BID%
Verapamil, amiodarone, quinidine,
P-glycoprotein inhibitors
For CrCl 30–50 mL/min: No dose adjustment needed, monitor clinical course For CrCl < 30 mL/min: Aviod
Not addressed in Package Insert
Reduce dose in for those starting on the full dose of 5 mg BID%
Clarithromycin
P-glycoprotein inducers and strong 3A4 inducers
For CrCl < 30 mL/min Avoid For CrCl 30–50 mL/min: No dose adjustment needed, monitor clinical course
Unclear: refer to package insert.
Reduce dose in for those starting on the full dose of 5 mg BID%
CrCl: creatinine clearance as determined by Crockcoft-Gault equation.
#Dabigatran etexilate (prodrug) uses the p-glycoprotein transport system. It is not a substrate, inducer, or inhibitor of the cytochrome p450 system. ∧Rivaroxaban is a substrate for cytochrome p450 as well as p-glycoprotein.
+Listed medications are representatives of potent 3A4 inhibitors and may not be comprehensive. %Those patients who need to start at 2.5 mg BID should avoid this combination.